Suchita Pakkala
Experienced in Fibrosarcoma

Dr. Suchita Pakkala

Oncology
Emory health
Winship Cancer Institute At Emory Midtown
36 Linden Avenue Northeast, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
22 Years of Experience
Experienced in Fibrosarcoma
Emory health
Winship Cancer Institute At Emory Midtown
36 Linden Avenue Northeast, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Suchita Pakkala is an Oncologist in Atlanta, Georgia. Dr. Pakkala has been practicing medicine for over 22 years and is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Paget Disease of the Breast.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Tennessee - Memphis College Of Med, 2004.0
Residency
Emory University School of Medicine
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2010
Fellowships
Emory University School of Medicine
Hospital Affiliations
Grady Memorial Hospital
Emory University Hospital Midtown
Emory University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Winship Cancer Institute at Emory Midtown
36 Linden Avenue Northeast, Atlanta, GA 30308
Call: 404-778-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Enrollment Status: Recruiting
Publish Date: November 28, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Navitoclax, Osimertinib
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 7 Less Clinical Trials

17 Total Publications

A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.
A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: June 13, 2022
View All 17 Publications
Similar Doctors
William L. Read
Distinguished in Fibrosarcoma
Dr. William L. Read
Oncology
Distinguished in Fibrosarcoma
Dr. William L. Read
Oncology

Winship Cancer Institute At Emory Midtown

36 Linden Avenue Northeast, Fl14, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Experience:
30+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Read is an Oncologist in Atlanta, Georgia. Dr. Read has been practicing medicine for over 30 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Bone Tumor, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Liposarcoma.

Felicia Williams
Distinguished in Fibrosarcoma
Felicia Williams, NP
Oncology
Distinguished in Fibrosarcoma
Felicia Williams, NP
Oncology

Winship Cancer Institute At Emory Midtown

36 Linden Avenue Northeast, Fl14, 
Atlanta, GA 
 (0.1 miles away)
404-778-1900
Languages Spoken:
English
See accepted insurances

Felicia Williams is an Oncologist in Atlanta, Georgia. Dr. Williams is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Alveolar Soft Part Sarcoma, Bone Tumor, Mesenchymoma, and Undifferentiated Pleomorphic Sarcoma.

Melinda L. Yushak
Advanced in Fibrosarcoma
Dr. Melinda L. Yushak
Oncology
Advanced in Fibrosarcoma
Dr. Melinda L. Yushak
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (3.4 miles away)
404-778-1900
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Melinda Yushak is an Oncologist in Atlanta, Georgia. Dr. Yushak has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Undifferentiated Pleomorphic Sarcoma, and Mesenchymoma.

VIEW MORE FIBROSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pakkala's expertise for a condition
ConditionClose
    • Distinguished
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Pakkala is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Angiosarcoma
      Dr. Pakkala is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Pakkala is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Lung Adenocarcinoma
      Dr. Pakkala is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Lung Cancer
      Dr. Pakkala is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    • Non-Small Cell Lung Cancer (NSCLC)
      Dr. Pakkala is
      Distinguished
      . Learn about Non-Small Cell Lung Cancer (NSCLC).
      See more Non-Small Cell Lung Cancer (NSCLC) experts
    View All 10 Distinguished Conditions
    • Advanced
    • EGFR Positive Lung Cancer
      Dr. Pakkala is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Inflammatory Breast Cancer
      Dr. Pakkala is
      Advanced
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Large-Cell Lung Carcinoma
      Dr. Pakkala is
      Advanced
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Laryngeal Cancer
      Dr. Pakkala is
      Advanced
      . Learn about Laryngeal Cancer.
      See more Laryngeal Cancer experts
    • Experienced
    • Adult Soft Tissue Sarcoma
      Dr. Pakkala is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Alveolar Soft Part Sarcoma
      Dr. Pakkala is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    • Bone Tumor
      Dr. Pakkala is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Chondrosarcoma
      Dr. Pakkala is
      Experienced
      . Learn about Chondrosarcoma.
      See more Chondrosarcoma experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Pakkala is
      Experienced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Endometrial Cancer
      Dr. Pakkala is
      Experienced
      . Learn about Endometrial Cancer.
      See more Endometrial Cancer experts
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.